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Abstract 
Adoptive cell transfer immunotherapy has been utilized to treat EBV related human malignancies 
including post-transplant lymphoproliferative diseases, Hodgkin lymphoma and nasopharyngeal 
carcinoma. However, there are limited options available for tumor antigen-specific T cell 
purification. Here we describe a novel solid phase T cell selection system, in which monocytes or 
EBV transformed B-lymphocytes are immobilized on solid support for antigen-specific T cell 
purification. We hypothesize and prove that antigen-specific T cells recognize their cognate 
antigens and bind to them faster than non-antigen specific T cells. Therefore antigen-specific T 
cells can be concentrated on the surface after removing the non-adherent cells by washing. 
Optimal selection time for both EBV-specific T cells and LMP2-specific T cells are studied. Our 
data demonstrated that frequency of antigen-specific T cells can be increased by >20-fold after 
selection. Moreover, activated antigen-specific T cells proliferate more rapidly than non-specific 
T cells, further increasing the frequency and purity of antigen-specific T cells. This new T cell 
selection system is superior to traditional repeated stimulation methods in generating tumor 
antigen-specific T cells. Particularly, we are able to generate large quantity of highly purified T 
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cells of subdominant antigens LMP2 within 2 weeks after T cell activation for adoptive cell 
transfer immunotherapy with his simple, rapid and inexpensive T cell selection system.  
 
Introduction 
Epstein-Barr virus (EBV) is associated with several human malignancies including Burkitt’s 
lymphoma, EBV-associated post-transplant lymphoproliferative diseases (PTLD), Hodgkin 
lymphoma (HL) and nasopharyngeal carcinoma (NPC). The cells of these tumors express a range 
of EBV latent gene products that have made them potential targets for T cell-mediated 
immunological therapies. Adoptive cell transfer (ACT) immunotherapy is based on the ex vivo 
selection of tumor-reactive lymphocytes, their activation and numerical expansion before 
reinfusion to the autologous tumor-bearing host. ACT immunotherapy has successfully prevented 
and treated PTLD occurring after hematopoietic stem cell and solid organ transplants (Rooney et 
al., 1995; Heslop et al., 1996; Rooney et al., 1998; Khanna et al., 1999; Gustafsson et al., 2000). 
In addition, Results from several clinical trials have proved autologous EBV-targeted T cells 
infusions effective in promoting clinical tumor response, including clinical remissions in some 
instances in patients with HL and NPC (Bollard et al., 2004a; Straathof et al., 2005; Bollard et al. 
2004b; Comoli et al., 2005). In these clinical trials, EBV-specific cytotoxic T lymphocytes 
(CTLs) are generated with peripheral blood mononuclear cells (PBMC) by repeated stimulation 
using patient-derived EBV transformed B lymphocyte (LCL) as antigen presenting cells. 
Unfortunately, LCL expresses complete range (latency III) of EBV latency genes: Epstein-Barr 
nuclear antigens (EBNAs) 1, 2, 3 (3A, 3B, 3C), EBNA-LP and the latent membrane proteins 
(LMP) 1 and 2, whereas EBV-associated HL and NPC tumor cells display limited (latency II) 
gene expression, in which EBV latent gene expression is restricted to the EBNA1, LMP1 and 
LMP2 proteins (Young et al., 1988; Fahraeus et al., 1988; Pallesen et al., 1991; Brooks et al., 
1992; Deacon et al., 1993; Grasser et al., 1994; Niedobitek et al., 1997). Furthermore, not only 
can it take several months to engineer EBV-specific cytotoxic T cells in sufficient quantity and 
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quality, but also there is very low frequency of tumor antigen-specific T cells (e.g. LMP2-specific 
T cells) in the final products. A major challenge to the development of ACT immunotherapy 
remains the need to produce tumor antigen-specific T cells not only in large quantity and high 
purity, but also inexpensively, simply and rapidly. 
 
Activation of T lymphocytes is mediated by the interaction of T cell antigen receptors (TcRs) 
with their ligands, major histocompatibility molecule-peptide complexes (MHC-peptide) through 
multiple stages (Grakoui et al., 1999). The initial molecular pattern as the consequences of TCR 
engagement with MHC-peptide can be described as an immature immunological synapse in 
which the TcR is engaged in the periphery of the extensive contact area. This is followed by 
formation of a mature immunological synapse in which the TcR is clustered in the center of the 
contact area over a period of hours (Monks et al., 1998; Grakoui et al., 1999). Full T cell 
activation leading to proliferation demands sustained TcR engagement and signaling that requires 
many minutes or hours (Lezzi et al., 1998). Thus the interval between initiation of the 
immunological synapse formation and T cell proliferation makes it possible to select antigen-
specific T cells by antigen presenting cells that are attached to a solid support, whereas the non-
adherent cells can be removed by washing. The underlying hypothesis of our novel T cell 
purification method is that: 1st, antigen-specific T cells recognize their cognate antigens and bind 
to them faster than non-antigen specific T cells; 2nd, activated antigen-specific T cells proliferate 
more rapidly than non-specific T cells. Among the choices of antigen presenting cells, both 
monocytes and LCL are readily available and can present antigens for T cell selection. While 
monocytes adhere to solid support spontaneously, LCL is non-adherent. To develop our solid 
phase T cell selection system, we synthesized an activated polyethylene glycol (PEG) polymer (2-
O-4,6-dichloro-s-triazine-polyethylene glycol-2-O-4,6-dichloro-s-triazine) to immobilize non-
adherent antigen presenting cells including LCL onto support surface.   
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Materials and Methods  
Study population  
PBMC was collected by apheresis from paid healthy donors at Thomas Jefferson University. 
Lymphocytes and monocytes that were seperated by Elutra® (Gambro) were processed by Ficoll-
Hypaque, frozen and stored in liquid nitrogen until use. This study has been reviewed and 
approved by IRB at Thomas Jefferson University. 
 
Peptides 
EBV LMP2 epitope peptides LLWTLVVLL (LLW), CLGGLLTMV (CLG), FLYALALLI 
(FLY), TVCGGIMFL (TVC) (restricted to HLA-A*0201, >90% purity) (Straathof et al., 2005) 
and Cytomegalovirus (CMV) pp65 peptide P495-503 NLVPMVATV (restricted to HLA-A*0201) 
were purchased from Biosynthesis Inc.  
 
Preparation of activated PEG polymer 
In a 500ml round bottom flask containing 150mL chloroform, sodium carbonate (7.066g), 2,4,6-
trichloro-1,3,5-triazine (2.459g), and PEG600 (4g, all from Sigma-Aldrich) were sequentially 
added. The mixture was stirred at room temperature for 48 hours, filtered, concentrated in a 
Rotary Evaporator and dried in vacuum. The final product was stored at -20oC until use. 
 
 
Antigen presenting cell immobilization 
1). Immobilizing LCL on glass through bovine serum albumin (BSA). 
A 100ml Pyrex® glass beaker, which was pre-treated with 20% sulfuric acid for 4 hours and 
rinsed in phosphate-buffered saline (PBS), was treated with 3 ml of 5% bovine serum albumin 
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(BSA) for 3 hours at room temperature. After removing BSA solution and rinsing with PBS, 5 ml 
PBS containing 0.4 gram of activated PEG polymer was added. PH was maintained between 8.5 
and 9 (monitored by pH strips) for 15 minutes at 20-25oC by adding sodium bicarbonate solution. 
After removing the solution, the beaker was rinsed with PBS. 30 x 106 irradiated LCL, which 
were washed twice with PBS and suspended in 2.5 ml PBS (pH8.5), were introduced into the 
beaker and were allowed to settle down for 3 minutes. The beaker (covered with a lid from 
Fisherbrand* Petri Dishes) was moved into the cell culture incubator (37 oC and 5% CO2) 
without disturbing the precipitated cells for another 20 minutes. Then non-adherent cells were 
removed and the beaker was gently rinsed with complete medium (RPMI 1640; Mediatech, Inc) 
containing 10% human normal AB serum (Gemini), and 2 mM L-glutamine. In general 5x106 
(mean) LCL cells can be immobilized on the surface of 100 ml glass beaker and cell viability 
(measured by Vi-Cell Counter) is consistently greater than 85% after immobilization. The 
immobilized cells were incubated with complete medium in the cell culture incubator for another 
60 minutes until use.  
2). Immobilizing LCL on glass through covalent binding. 
A clean, dry 100ml beaker (treated with sulfuric acid previously) was treated with dilute (1-4% in 
dry acetone) 3-aminopropyltriethoxysilane for about 15 min, rinsed in acetone, water and then 
followed by the addition of activated PEG polymer solution described above.   
3). Immobilizing monocytes in 6-well-plates. 
10 x106 monocytes were thawed and immediately added to one well of a 6-well-plate (BD 
Falcon™ Primaria®) in 3 mL of complete medium containing DNAse I (960 U) (Worthington 
Biochemical Corporation). After 90 minutes in the cell culture incubator, the medium was 
removed and adherent cells were rinsed with warm (37oC) PBS, pulsed with 2µM peptide for 90 
minutes until use. 
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Generation of EBV-transformed B cell lines. 
5-10 x106 PBMC was incubated with concentrated supernatant of B95-8 cultures, in the presence 
of 1µg/mL cyclosporin A (Sandoz) to establish an LCL.  
 
Generation of EBV-specific CTLs and LMP2-specific CTLs by traditional repeated 
stimulation method. 
PBMC was co-cultured with irradiated (80 Gy) autologous LCL or monocytes that were 
previously pulsed with a LMP2 epitope peptide (2µM) at a responder/stimulator ratio of 10:1. 
Starting on day 7, the responder cells were re-stimulated with irradiated LCL at a 
responder/stimulator ratio of 4:1 or monocytes pulsed with target peptide at a 
responder/stimulator ratio 10:1. Two weekly doses of recombinant human IL-2 (rhIL-2) at 
20U/ml (Proleukin; Chiron) were added from day 7. On day 14, the responder cells were 
analyzed by flow cytometric intracellular cytokine assay for IFN-γ production. 
 
Antigen-specific T cell selection and expansion (Figure 1) 
PBMC was activated with irradiated LCL or peptide-pulsed-monocytes as described above. On 
day 7, activated lymphocytes (90 x 106 + 10 in 3 mL complete media, 37oC) were added onto 
immobilized antigen presenting cells in cell culture incubator (For LMP2-specific CTLs selection 
by LCL, LCL was pulsed with 2µM peptide for 4 hours before immobilization. LCL was then 
irradiated, immobilized and exposed again with CLG for 1 hour; For LMP2-specific CTLs 
selection by monocytes, peptide treatment of monocyte was described in monocyte 
immobilization section). Various selection times were tested. Non-adherent cells were removed at 
the end of each selection time. The remaining adherent cells were gently washed with 37oC 
culture media. Washing was repeated after 30 minutes incubation at 37oC because some of non-
specific T cells selected by antigen presenting cells will disengage and float again. The next day, 
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adherent cells were removed by gentle agitation and transferred to a 75 cm2culture flask 
(Corning®) in 100 mL complete media. RhIL-2 (20U/ml) was added at the time and thereafter 
every 2-3 days. On day 7 for EBV-specific T cells and day 8 for LMP2-specific T cells, cultured 
cells were analyzed by ICC with addition of autologous LCL or peptide-pulsed-monocytes as 
antigen presenting cells. 
 
Intracellular cytokine staining (ICC) 
1). Intracellular IFN-γ staining was done as described (Li et al., 2006). Briefly, 2 x 106 
lymphocytes were cultured with irradiated autologous LCL (for EBV-specific CTLs, 
lymphocytes:LCL 1/1) or irradiated peptide-loaded-monocytes (for LMP2-specific CTLs, 
lymphocytes:monocytes 1/1). After 2 h, 10 µg/ml brefeldin A (Sigma) was added and cultures 
were incubated for a further 4 h. After this period, cells were stained with CD3-PerCP and CD8-
PE, fixed in FACS Lyse, permeabilized with FACS Perm2 and labelled with anti-IFN-c–
fluorescein isothiocyanate (all from Becton Dickinson) according to the intracellular-staining 
procedure protocol supplied by the manufacturer. Immunofluorence measurement were acquired 
on a FACScalibur flow cytometer and analyzed using CellQuest software. The frequency 
determined for the unstimulated control was subtracted from the frequency for the LCL or LMP2 
peptides-stimulated population to determine the true antigen-specific T-cell frequency. 
 
2). The procedure for intracellular IFN-γ staining of selected lymphocytes by immobilized LCL 
or monocytes on the solid support was modified from the procedure described above. After 
selecting lymphocytes with immobilized antigen presenting cells, non-adherent cells were 
removed at the end of each selection time. The remaining adherent cells were gently washed with 
37oC culture media. Washing was repeated after 30 minutes incubation at 37oC. At 2 hours after 
selection, after removing culture media, 6 ml culture media containing 10µg/ml brefeldin A was 
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added and cultures were incubated for a further 4 h. This was then followed by the procedure of 
cell staining with antibody, lysing and permeation described above.  
 
Tetramer staining 
PE-labeled EBV HLA-A2-tetramer (LMP2 peptide CLGGLLTMV, Beckman Coulter) was used 
to detect CLG–specific T cells in the CTL lines. PE-labeled M27L HLA-A2-tetramer (Melan-A, 
26–35 variant ELAGIGILTV, Beckman Coulter) was used as tetramer control. Tetramer staining 
was done as described by the manufacturer. Briefly, CTLs (106) were incubated at room 
temperature for 30 minutes in (PBS)/1% fetal calf serum (FCS) containing the PE–labeled 
tetrameric complex. Samples were co-stained with anti-CD8 FITC and anti-CD3 PerCP. Stained 
cells were fixed in PBS containing 0.5% paraformaldehyde. Cells were acquired on a 
FACScalibur flow cytometer and analyzed using Cell Quest software. 
 
Chromium Release Assay. 
The cytotoxic specificity of each CTL line was analyzed in a standard 4-h chromium-51 release 
assay (Brunner et al., 1968). The following target cells were tested: autologous LCL; K562, 
which is sensitive to killing by lymphokine-activated killer cells; and T2 cell line pulsed with 
CMV peptide as a control for LMP2-specific T cells generated by the solid phase T cell selection 
method.  
 
Results 
 
EBV-specific CTL selection 
One of the most commonly used methods to generate EBV-specific T cells is to stimulate PBMC 
repeatedly (usually weekly) with autologous LCL. This is followed by T cell expansion in the 
presence of rhIL-2. In our new T cell purification method we exploited immobilized irradiated 
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LCL to select EBV-specific T cells first, followed by T cell expansion. We have performed T cell 
selection experiments with PBMC from 3 healthy donors (3 times each for donor 1, 5 and 6). 
Here we present data from donor 1 (HLA*A0201+) to illustrate the process of T cell selection. 
General scheme of solid phase T cell selection process was outlined in Figure 1. The mean 
frequency of EBV-specific CTLs was determined to be 1.8% by ICC 7 days after PBMC of donor 
1 was stimulated with irradiated autologous LCL. To test our first hypothesis, we examined the 
frequency of EBV-specific T cells selected at various selection times (ranging from 1 to 15 
minutes) by immobilized LCL. After non-adherent cells were removed at the end of each 
selection time, intracellular IFN-γ staining of selected lymphocytes on the support surface was 
performed based on the modified procedure described in Method section. There were 22%, 44%, 
20%, 12% and 8% (mean) IFN-γ producing cells among cells selected at 1, 3, 5, 10 and 15 
minutes, respectively (Figure 2A). Subsequently, we expanded these selected lymphocytes (we 
did not expand T cells selected at 1 minute because of the scarcity of selected cells). This was 
accomplished by adding rhIL-2 (20u/ml) one day after selection and then every 2-3 days 
thereafter. On day 7, we analyzed these expanded cells by ICC for IFN-γ production. IFN-γ 
producing cells were increased to 80%, 65%, 50%, and 45% (mean) among the expanded cells of 
selection times 3, 5, 10 and 15 minutes, respectively (Figure 2B), whereas there were only 15% 
(mean) IFN-γ producing cells of lymphocytes generated by traditional method (data not shown). 
There were 30 x106, 100 x106, 120x106 and 120x106 (mean) cells in final expanded cell 
population selected at 3, 5, 10 and 15 minutes, respectively. Of cells that were selected from 3 to 
5 minutes and expanded for 7 days, >90% (mean) of cell population is CD3+CD8+ (data not 
shown). To test our 2nd hypothesis, we measured the IFN-γ production from cells selected at 5 
minutes starting right after T cell selection (day 0), then day 1, 2 and 7 after selection by exposing 
them to autologous LCL. There were 20%, 22%, 45%, and 65% (mean) IFN-γ producing cells 
among cells selected on day 0, 1, 2 and 7, respectively (Figure 2D). Of note, there were only 
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0.6% and 0.8% IFN-γ producing cells in non-stimulated lymphocytes (i.e. negative control) 24 
and 48 hours after selection (data not shown). Figure 2E shows that T cells generated from this 
new method recognize and kill autologous LCL, whereas there are no significant killings toward 
K562 and autologous LCL when MHC I antibody (w6/32) was added to the LCL.  
 
Similar patterns were also observed in T cell selection experiments using PBMC from donor 5 
and 6 and highest IFN-γ production was observed at 3 minutes selection time. In donor 5 and 6, 
there were 1.3% and 1% of EBV-specific T cells, respectively after PBMC was stimulated with 
autologous LCL. IFN-γ producing cells were increased to 23% and 30% (mean) among cells 
selected at 3 minutes on support surface (data not shown) for donor 5 and 6, respectively. In 
donor 5 and 6, we only expanded cells selected at 5 minutes to examine the frequency of EBV-
specific T cells because there was less than desired amount of cells in the final expanded cell 
population selected from 3 minutes. Right after selection at 5 minutes, there were 20% and 18% 
(mean) IFN-γ producing cells among cells on support surface (data not shown) for donor 5 and 6, 
respectively. After 7 days expansion, there were 120x106 (mean) cells in final expanded cell 
population for both donors 5 and 6. The percent EBV-specific T cells were increased to 55% and 
50% (mean) for donor 5 and 6, respectively, whereas there were only 19% and 12% (mean) EBV-
specific T cells in lymphocytes generated by traditional method for donor 5 and 6, respectively 
(data not shown).     
 
Next we measured the quantities of LMP2-specific T cells in lymphocytes generated from both 
solid phase T cell selection method and traditional method. In donor 1, T cell responses to LMP2 
epitope peptides LLW, CLG, and FLY were observed. We used autologous monocytes that were 
pulsed with peptides LLW, CLG, and FLY together as antigen presenting cells to stimulate T 
cells for IFN-γ production. There were 17%, 19%, 9% and 7% (mean) IFN-γ producing cells in 
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lymphocytes generated from 3, 5, 10 and 15 minutes selection (Figure 2C), whereas there were 
only 1.2% (mean) IFN-γ producing cells in lymphocytes generated by traditional method (data 
not shown). In donors 5 and 6 (both are HLA *A0201+), T cell responses to LMP2 epitope 
peptides LLW, CLG, FLY and TVC were seen. Again we used autologous monocytes that were 
pulsed with peptides LLW, CLG, FLY and TVC together as antigen presenting cells to stimulate 
T cells for IFN-γ production. Of lymphocytes generated by 5 minutes selection time, there were 
16% and 19% (mean) IFN-γ producing cells for donor 5 and 6, respectively, whereas there were 
only 1% and 0.6% IFN-γ producing cells in lymphocytes generated by traditional method for 
donor 5 and 6, respectively (data not shown).  
 
 
LMP2-specific CTL selection 
We decided to apply our new T cell purification method to select LMP2-specific T cells directly. 
The general strategy is to activate PBMC with LMP2 epitope peptide-loaded-monocytes first. 
This would be followed by selection of LMP2-specific T cells with either immobilized 
autologous LCL or monocytes pulsed with target peptide. Of multiple T cell selection 
experiments with PBMC from several healthy donors, we present data from donor 5 to illustrate 
the T cell selection process. The frequency of CLG-specific T cells was determined to be 0.8% 
(mean) by ICC 7 days after PBMC of donor 5 was stimulated with CLG-loaded-monocytes. First 
we tested autologous irradiated LCL as antigen presenting cells for CLG-specific T cell selection. 
We examined various selection times to determine the optimal selection time. After removing 
non-adherent cells at the end of each selection time, intracellular IFN-γ staining of selected 
lymphocytes on the support surface was performed. IFN-γ producing cells were increased to 10%, 
17%, 24%, 21% and 19% (mean) among cells selected at 3, 5, 7.5, 10 and 15 minutes, 
respectively (Figure 3A). Because LCL could also present EBV antigens other than CLG peptide 
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and induce IFN-γ production among selected T cells, we examined the quantity of IFN-γ 
production that might be contributed by EBV antigens other than CLG. We selected non-
stimulated-PBMC with immobilized LCL with selection time of 7.5 minutes and measured the 
quantity of IFN-γ positive cells. There were only 0.4% (mean) IFN-γ positive cells among the 
selected cells (data not shown). Subsequently, we expanded these selected lymphocytes (we did 
not expand T cells selected with selection time less than 5 minutes because of the scarcity of 
selected cells). This was accomplished by adding rhIL-2 (20u/ml) one day after selection and then 
every 2-3 days thereafter. On day 8, we analyzed these expanded cells from various selection 
times by both ICC for IFN-γ production and tetramer staining. IFN-γ producing cells were 
increased to 55%, 70% and 65% (mean) among final expanded cells of selection times 5, 7.5 and 
10 minutes (Figure 3B), respectively, whereas there were only 12% IFN-γ producing cells of 
lymphocytes generated by traditional method (data not shown). Tetramer staining yielded 82% 
(mean) of CLG-specific T cells among cells generated from 7.5 minutes selection (Figure 3B). 
CLG-specific T cells generated from this new method lysed T2 cell line pulsed with CLG, 
whereas there were no significant lysis of T2 cell line pulsed with CMV peptide P495-503 (Figure 
3C). There were 80 x106, 100x106 and 100x106 (mean) cells in final expanded cell population 
selected at 5, 7.5 and 10 minutes, respectively. More than 90% (mean) of these cell populations is 
CD3+CD8+ (data not shown). 
  
Next, we tested autologous monocytes as antigen presenting cells for CLG-specific T cell 
selection. Again, we examined various selection times to determine the optimal selection time. 
After removing non-adherent cells at the end of each selection time, intracellular IFN-γ staining 
of selected lymphocytes on the support surface was performed. IFN-γ producing cells were 
increased to 5%, 13%, 15%, 23% and 19% (mean) among cells selected at 1, 3, 5, 7.5 and 15 
minutes, respectively (Figure 4A). Because monocytes could also present antigens other than 
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CLG peptide and induce IFN-γ production among selected T cells, we examined the quantity of 
IFN-γ production that might be contributed by antigens other than CLG. There was less than 
0.2% (mean) of IFN-γ production when CLG-stimulated-PBMC was selected with immobilized 
plain monocytes (selection time of 7.5 minutes, data not shown). Subsequently, we expanded 
these selected lymphocytes (we did not expand T cells selected with selection time less than 5 
minutes because of the scarcity of selected cells). This was accomplished by adding rhIL-2 
(20u/ml) one day after selection and then every 2-3 days thereafter. On day 8, we analyzed these 
expanded cells from various selection times by both ICC for IFN-γ production and tetramer 
staining. IFN-γ producing cells were increased to 60%, 68% and 45% (mean) among expanded 
cells of selection times 5, 7.5 and 15 minutes (Figure 4B), respectively, whereas there were only 
12% IFN-γ producing cells of lymphocytes generated by traditional method (data not shown). 
Tetramer staining yielded 87% (mean) of CLG-specific T cells among cells generated from 7.5 
minutes selection (Figure 4B). CLG-specific T cells generated from this new method lysed T2 
cell line pulsed with CLG, whereas there were no significant lysis of T2 cell line pulsed with 
CMV peptide P495-503 (Figure 4C). There were 40 x106, 80x106 and 80x106 (mean) cells in final 
expanded cell population selected at 5, 7.5 and 15 minutes, respectively. More than 90% (mean) 
of these cell populations is CD3+CD8+ (data not shown). 
 
Discussion 
In the past two decades, adoptive T cell therapy targeting malignancies such as melanoma and 
EBV related malignancies has shown promising potential. However, it has been a great challenge 
to produce functional tumor antigen-specific T cells inexpensively, simply and rapidly. While 
several approaches to generate tumor-specific CTLs have been successfully introduced in clinical 
experimental protocols, the establishment of a broadly applicable process is still lacking. There 
are significant limitations in MHC-tetramer and its related technology such as artificial antigen 
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presenting cells. They are costly and limited to a few HLA phenotypes. The IFN-γ capture 
method has been shown to be inefficient and nonspecific in T cell selection.  Based on our 
hypothesis, we have established a simple yet effective antigen-specific T cell selection system. To 
our best knowledge, this monocyte and LCL based T cell selection system is the first reported so 
far. However, application of solid phase technology can be dated back to Bruce Merrifield’s solid 
phase peptide synthesis (Merrifield, 1963). In life science, application of solid phase technology 
is widely seen in almost every fields, involving protein, antibody, DNA and RNA, etc.  Data 
presented here supports our hypothesis that antigen-specific T cells can be selected by antigen 
presenting cells preferentially. Moreover, because activated antigen-specific T cells proliferate 
more rapidly than non-specific T cells, the final frequency and purity of antigen-specific T cells 
can be increased up to 80% just in 2 weeks, with magnitude of CTLs in the order of 108 from 
each selection and expansion. Shortly after we completed this report, we also completed another 
report in which we demonstrated that large-scale highly purified Melan-A-specific T cells could 
be generated with monocyte based solid phase T cell selection system within 2 weeks after T cell 
activation. The short time frame required to generate large-scale highly purified tumor reactive T 
cells with our method is unprecedented. Of the published clinical trial protocols, it takes a 10–12 
week period of in vitro culture with high-dose IL-2 to yield 1010-1011 tumor-infiltrating 
lymphocytes (Topalian et al, 1987). This time frame can be cut by half when tumor-infiltrating 
lymphocytes are expanded using anti-CD3 in combination with irradiated feeder cells to achieve 
similar numbers (Dudley et al, 2002). Although T cell clones can be expanded over two weeks to 
achieve numbers >1010, there are additional weeks needed to generate the clones first and the 
cloning process is laborious (Yee et al, 2002). Mackensen and his colleagues (Mackensen et al, 
2006) established a protocol to generate M27L-specific T cells by stimulating CD8+ lymphocytes 
(selected by beads) with dendritic cells weekly for 4 weeks. Of 11 patients treated, there were a 
total of 52 infusions, with an average of 2x108 M27L-specific T cells in each infusion. As 
aforementioned, it takes several months to generate adequate amount of EBV-specific T cells by 
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protocols of repeated stimulation method for trials in EBV related malignancies. Another 
important factor regarding ACT is the underlying cost associated with T cell preparation. This 
becomes particularly important nowadays in the era of targeted cancer therapy, which could exert 
enormous financial impact on the health care system.  For example, the monthly cost of Sorafenib 
and Sunitinib is about $8000 in the United States. Administration of a complete course of 
Bevacizumab, Herceptin and Cetuximab costs more than one hundred thousand dollors. Relevant 
to our T cell selection system, the cost of apheresis is about $500. The cost of Elutra device is 
about $23,000 and each monocyte elutriation kit is ~$1000. The total cost for each patient (if 
using monocyte based T cell selection system) is about $1500+23000/n (n is the total number of 
patients to be treated). This would be closer to $1500 if large number of patients were treated. We 
believe that our method is superior to the currently known protocols exploited in cancer therapy 
when considering all critical factors in ACT, i.e. time required for cell production, quantity and 
quality of cell product, technical difficulty of protocol being used, and cost. It is reasonable to 
conclude that our method is indeed simple, rapid and relatively inexpensive compared to the 
published clinical trial protocols.  
 
Of the EBV antigens expressed in EBV-associated HL and NPC tumor cells, namely EBNA1, 
and latent proteins (LMPs) 1 and 2, processing of EBNA1 through the HLA class I pathway is 
inhibited by a glycine-alanine repeat. Therefore peptides from EBNA1 are presented to CD8 T 
cells from incompletely translated proteins (Levitskaya et al., 1995; Voo et al., 2004; Lee et al., 
2004; Tellam et al., 2004). This makes EBNA1 a less attractive target for immunotherapy. LMP1 
is not an ideal target either, mainly because LMP1 displays heterogeneity between virus strains, 
so that T cells raised against B-cell (B95-8 prototype)-derived LMP1 may not recognize the 
LMP1 tumor variants (Trivedi et al., 1994; Khanim et al., 1996). Epitopes of LMP2, however, are 
conserved between viral strains (Lee et al., 1993; Busson et al., 1995). Furthermore, the existence 
of LMP2-specific T cells in patients with HL and NPC have previously been reported (Sing et al., 
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1997; Whitney et al., 2002). Therefore the quantity of LMP2-specific T cells might be viewed as 
the most important element of the final cell culture product for ACT. In this paper, we have 
demonstrated 2 approaches to produce LMP2-specific T cells. One started with selection of LCL 
activated EBV-specific T cells. In this approach, the quantities of LMP2-specific T cells represent 
only minority of EBV-specific T cells, which is consistent with the fact that LMP2 are EBV 
subdominant antigens. Even so, the quantities of LMP2-specific T cells generated from this new 
T cell selection method appears to be much more than that in EBV-specific T cells generated 
through traditional repeated stimulation method, in which on average only about 1% of LMP2-
specific T cells was generated using PBMC from both normal individual and Hodgkin’s 
Lymphoma patients (Bollard et al., 2004b).  In patients with known HLA restricted LMP2 
epitope peptide, another approach is to select and expand activated LMP2-specific T cells 
directly. Data presented in this paper demonstrated that our monocyte or LCL based T cell 
selection system can produce large quantity of high purity LMP2-specific T cells within 2 weeks 
after T cell activation. The specificity of these purified LMP2-specific T cells were confirmed by 
ICC, tetramer staining and cytotoxicity experiments. The discrepancy between the findings of 
purity of LMP2-specific T cells by ICC and tetramer staining can be attributed to TcR 
promiscuity. There are several significant clinical implications here. First, very few LMP2-
specific T cells can be generated through traditional repeated stimulation method because LMP2 
is a subdominant antigen. Moreover, patients with refractory or recurrent HL and NPC usually 
progress rapidly and may not survive long enough to have their ACT products prepared by 
traditional repeated stimulation method. Our novel T cell selection system could have immediate 
therapeutic implications in these patients with refractory or recurrent HL and NPC.        
 
By comparing the selection of EBV-specific T cells and LMP2-specific T cells, it seems that the 
selection time (Tmax) at which highest IFN-γ positive cells can be generated during T cell 
selection is much shorter for EBV-specific T cell selection. There are 2 major factors that may 
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play significant roles in regulating Tmax. Namely they are the rate of antigen-specific T cell 
selection and non-specific T cell selection. Although EBV-specific T cells and LMP2-specific T 
cells are activated with different antigen presenting cells (i.e. autologous LCL and monocytes, 
respectively), it is reasonable to assume that those non-specific T cells should possess similar 
properties in interacting with antigen presenting cells and therefore should display similar 
selection rates by the same antigen presenting cells. If this assumption holds true, Tmax can be 
viewed as a surrogate of rate of antigen-specific T cell selection. In addition, we would like to 
caution on notions that high avidity T cells are selected preferentially here. The avidity of the 
interaction between T cell and antigen presenting cells is the sum of multiple factors including 
interactions between TcR and its MHC/peptide ligand, co-receptors, costimulatory and adhesion 
molecules, as well as signaling machinery and others. It is intuitive to consider that the high 
avidity T cells should be selected first with our method. Yet this notion ignores a most important 
factor in our experiments. That is T cells, including high and low avidity T cells, are initially 
evenly dispersed in media (3 ml) and introduced to antigen presenting cell layer. We observed 
that it takes at least 5 minutes for T cells to precipitate and form a uniform layer on top of antigen 
presenting cell layer. There are no indications which cells, high avidity or low avidity T cells, can 
precipitate faster to the surface to interact with antigen presenting cells. In addition, our data 
show that there are significant amount of antigen-specific T cells that have already been 
interacting with antigen presenting cells at 1 minutes of co-culturing. We believe that the T cells 
selected this way are mostly by chance of their geography, i.e. how close their distance is with 
antigen presenting cells. T cell avidity, on the other hand, may only play a minor role. Our data 
here indicate that selection of EBV-specific T cells, in which the majority are T cells specific for 
EBV’s dominant antigens, is faster than selection of LMP2 (subdominant antigen)-specific T 
cells. This may partly explain the difference of CTLs responses to EBV’s dominant and 
subdominant antigens since previous studies suggested that the “recruitment time” determined the 
magnitude of cellular immune response to a particular antigen (Bousso et al., 1999; De Boer et 
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al., 2001). In addition, it appeared that there was a significant delay of proliferation for LMP2-
specific T cells compared to EBV-specific T cells right after T cell selection (unpublished 
observation). This phenomenon of delayed initiation of cell division of T cells responding to 
subdominant antigen was also reported in a previous study (Hommel et al., 2003). Because of 
delayed proliferation for LMP2-specific T cells, we decided to expand the selected LMP2-
specific T cells to day 8 instead of day 7 after selection before analyzing their purity and quantity. 
Clearly these differences between LMP2-specific T cells and EBV-specific T cells merit further 
studies in the future, particularly in the area of T cell selection kinetics and proliferation after T 
cell activation. In view of these selection kinetic differences between EBV-specific T cells and 
LMP2-specific T cells, one might raise questions of the optimal selection time for non-EBV 
related antigen-specific T cells. Moreover, do similar selection kinetic differences exist among T 
cells of other dominant and subdominant antigens? More studies are needed to answer these 
questions.  
 
In addition to select peptide specific T cells, our method provides a platform for protein-specific 
T cells selection. Protein-specific T cell selection should be feasible even though we did not 
perform such experiments here. Monocytes can adhere on surface for a few hours before 
becoming floating cells, while it takes 18-24 hours for them to uptake, process and present the 
protein antigens. The activated PEG polymer, however, is able to immobilize them onto solid 
support for T cell selection. Because majority of the T cells generated this way are likely CD4+ T 
cells, additional intervention to promote cross-presentation, e.g. exploiting liposome technology 
might be needed.         
 
Finally we introduced a novel monocyte and LCL based antigen-specific T cell selection system. 
Our data demonstrated this new T cell selection system is superior to traditional repeated 
stimulation method in generating antigen-specific T cells. Not only can this novel T cell selection 
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system purify CD8+ antigen-specific T cells, but also select and purify CD4+ antigen-specific T 
cells (Li et al., 2006). Although the efficacy of T cell selection from both monocyte and LCL 
based selection systems appears comparable to each other, there are obvious advantages and 
disadvantages in each selection system. Monocytes are readily available. However purification of 
monocytes requires additional elutriation after apheresis, which increases cost. In addition, in 
some heavily chemotherapy-treated cancer patients, cytopenia may preclude monocyte 
elutriation. In this situation, LCL based T cell selection system would help to solve the problem. 
In addition, expansion followed by T cell selection with LCL based system generated more cells 
than monocyte based system. The main disadvantage with LCL is that it requires 3 to 4 weeks to 
establish adequate amount of transformed B cell lines. Nevertheless, we believe that this novel T 
cell selection system provides a valuable means to generate high quality antigen-specific T cells 
simply, rapidly and inexpensively. More importantly, this novel T cell selection system can work 
broadly with other antigens as noted above, and is not just limited to EBV related antigens. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 20 
Reference 
Bollard CM, Straathof KC, Huls MH, et al. 2004a. The generation and characterization of LMP2-
specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin 
disease. J Immunother. 27:317. 
 
Bollard CM, Aguilar L, Straathof KC, et al. 2004b. Cytotoxic T lymphocyte therapy for Epstein-
Barr virus Hodgkin’s disease. J Exp Med. 200:1623. 
 
Brooks L, Yao QY et al. 1992. Epstein-Barr virus latent gene transcription in nasopharyngeal 
carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol. 66:2689. 
 
Bousso P, Levraud JP, Kourilsky P, Abastado JP. 1999. The composition of a primary T cell 
response is largely determined by the timing of recruitment of individual T cell clones. J. Exp. 
Med. 189:1591. 
 
Brunner KT, Mauel J, Cerottini JC, Chapuis B. 1968. Quantitative assay of the lytic action of 
immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by 
isoantibody and by drugs. Immunology. 14:181 
 
Busson P, Edwards RH, Tursz T, et al. 1995. Sequence polymorphism in the Epstein-Barr virus 
latent membrane protein (LMP)-2 gene. J Gen Virol. 76:139. 
 
Comoli P, Pedrazzoli P, et al. 2005. Cell therapy of stage IV nasopharyngeal carcinoma with 
autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol. 23:8942 
 
Deacon EM, Pallesen G, Niedobitek G, Crocker J, Brooks L, Rickinson AB, Young LS. 1993. 
Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the 
malignant cells. J Exp Med. 177:339. 
 
De Boer RJ, Oprea M, Antia R, Murali-Krishna K, Ahmed R, Perelson AS. 2001. Recruitment 
times, proliferation, and apoptosis rates during the CD8(+) T-cell response to lymphocytic 
choriomeningitis virus. J Virol. 75:10663. 
Dudley ME, Wunderlich JR, Robbins PF, et al. 2002. Cancer regression and autoimmunity in 
patients after clonal repopulation with antitumor lymphocytes. Science. 298:850-854. 
 
Fahraeus R, Fu HL et al. 1988. Expression of Epstein-Barr virus-encoded proteins in 
nasopharyngeal carcinoma. Int J Cancer. 42:329. 
 
Grakoui, A., S.K. Bromley, C. Sumen, et al. 1999. The immunological synapse: a molecular 
machine controlling T cell activation. Science  285:221 
 
Grasser FA, Murray PG et al. 1994. Monoclonal antibodies directed against the Epstein-Barr 
virus-encoded nuclear antigen 1 (EBNA1): immunohistologic detection of EBNA1 in the 
malignant cells of Hodgkin's disease. Blood. 84:3792. 
 
Gustafsson, A., V. Levitsky, J.Z. Zou, T. Frisan, T. Dalianis, P. Ljungman, O. Ringden, J. 
Winiarski, I. Ernberg, and M.G. Masucci. 2000. Epstein-Barr virus (EBV) load in bone marrow 
transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic 
infusion of EBVspecific cytotoxic T cells. Blood. 95:807. 
 
 21 
Heslop, H.E., C.Y.C. Ng, C. Li, C.A. Smith, S.K. Loftin, R.A. Krance, M.K. Brenner, and C.M. 
Rooney. 1996. Longterm restoration of immunity against Epstein-Barr virus infection by adoptive 
transfer of gene-modified virus-specific T lymphocytes. Nat. Med. 2:551. 
  
Hommel M, Kyewski B. 2003. Dynamic changes during the immune response in T cell-antigen-
presenting cell clusters isolated from lymph nodes. J Exp Med. 197:269. 
 
Johnson D, Mendicino J, Cormier M, and Travis J. 1974. Fed. Proc  33:1502 
 
Kay G and Lilly MD. 1980. Biochim. Biophys. Acta. 198: 276 
 
Khanim F, Yao QY, Niedobitek G, et al. 1996. Analysis of Epstein-Barr virus gene 
polymorphisms in normal donors and in virus-associated tumors from different geographic 
locations. Blood. 88:3491. 
 
Khanna, R., S. Bell, M. Sherritt, A. Galbraith, S.R. Burrows, L. Rafter, B. Clarke, R. Slaughter, 
M.C. Falk, J. Douglass, et al. 1999. Activation and adoptive transfer of Epstein-Barr virus-
specific cytotoxic T cells in solid organ transplant patients with posttransplant 
lymphoproliferative disease. Proc. Natl. Acad. Sci. USA. 96:10391. 
 
Lee SP, Thomas WA, Murray RJ, et al. 1993. HLA A2.1-restricted cytotoxic T cells recognizing 
a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein 
LMP2. J Virol. 67:7428. 
 
Lee SP, Brooks JM, Al Jarrah H, et al. 2004. CD8 T cell recognition of endogenously expressed 
Epstein-Barr virus nuclear antigen 1. J Exp Med. 199:1409. 
 
Levitskaya J, Coram M, Levitsky V, et al. 1995. Inhibition of antigen processing by the internal 
repeat region of the Epstein-Barr virus nuclear antigen-1. Nature. 375: 685. 
 
Lezzi G, Karjalainen K, Lanzavecchia A. 1998. The Duration of Antigenic Stimulation 
Determines the Fate of Naive and Effector T Cells. Immunity. 8: 89. 
 
Li J, Melenhorst J, Hensel N, Rezvani K, et al. 2006. T cell responses to peptide fragments of the 
BKV T antigen – implications for cross-reactivity of immune response to JC virus. J Gen Virol 
87: 2951. 
 
Li J, Mookerjee B, Wagner J. 2007. Purification of melanoma reactive T cell by using a 
monocyte-based solid phase T cell selection system for adoptive therapy. J. Immunotherapy. In 
press 
 
Mackensen A, Meidenbauer N, Vogl S, et al. 2006. Journal of Clinical Oncology.  24:5060 
 
Merrifield, RB. 1963. J. Am. Chem. Soc. 85, 2149 
 
Monks, C.R., B.A. Freiberg, H. Kupfer, et al. 1998. Three-dimensional segregation of 
supramolecular activation clusters in T cells. Nature. 395:82. 
 
Mur VI. Russ. 1964. Chem. Rev. 33:92 
 
 22 
Niedobitek G, Kremmer E, Herbst H, Whitehead L, Dawson CW, Niedobitek E, von Ostau C, 
Rooney N, Grasser FA, Young LS. 1997. Immunohistochemical detection of the Epstein-Barr 
virus-encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis. 
Blood. 90:1664. 
 
Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS. 1991. Expression of Epstein-Barr virus 
latent gene products in tumour cells of Hodgkin's disease. Lancet. 337:320. 
 
Rooney, C.M., C.A. Smith, C. Ng, S.K. Loftin, C. Li, R.A. Krance, M.K. Brenner, and H.E. 
Heslop. 1995. Use of genemodified virus-specific T lymphocytes to control Epstein-Barr virus-
related lymphoproliferation. Lancet. 345:9. 
 
Rooney, C.M., C.A. Smith, C.Y.C. Ng, S.K. Loftin, J.W. Sixbey, Y.-J. Gan, D.-K. Srivastava, 
L.C. Bowman, R.A. Krance, M.K. Brenner, and H.E. Heslop. 1998. Infusion of cytotoxic T cells 
for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant 
recipients. Blood. 92:1549. 
 
Sing AP, Ambinder RF, Hong DJ, et al. 1997. Isolation of Epstein-Barr virus (EBV)-specific 
cytotoxic T lymphocytes that lyse Reed-Sternberg cells: Implications for immune-mediated 
therapy of EBV Hodgkin’s disease. Blood. 89:1978. 
 
Straathof KC, Bollard CM, et al. 2005. Treatment of nasopharyngeal carcinoma with Epstein-
Barr virus--specific T lymphocytes. Blood. 105:1898.  
 
Tellam J, Connolly G, Green KJ, et al. 2004. Endogenous presentation of CD8+ T cell epitopes 
from Epstein-Barr virus-encoded nuclear antigen 1. J Exp Med. 199:1421. 
 
Topalian SL, Muul LM, Solomon D, Rosenberg SA. 1987. Expansion of human tumor infiltrating 
lymphocytes for use in immunotherapy trials. Journal of Immunological Methods. 102:127-141. 
 
Trivedi P, Hu LF, Christensson B, et al. 1994. Epstein-Barr virus (EBV)-encoded membrane 
protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, 
in contrast to a B cell derived homologue. Eur J Cancer. 30A:84. 
 
Voo KS, Fu T, Wang HY et al. 2004. Evidence for the Presentation of Major Histocompatibility 
Complex Class I-restricted Epstein-Barr Virus Nuclear Antigen 1 Peptides to CD8_ T 
Lymphocytes. J Exp Med. 199:459. 
 
Whitney BM, Chan ATC, Rickinson AB, et al. 2002. Frequency of Epstein-Barr virus-specific 
cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal 
carcinoma patients. J Med Virol 67:359  
 
Yee C, Thompson JA, Byrd D, et al. 2002. Adoptive T cell therapy using antigen-specific CD8+ 
T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, 
migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 2002, 
99:16168-16173 
 
Young LS, Dawson CW, Clark D, Rupani H, Busson P, Tursz T, Johnson A, Rickinson AB. 
1988. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol. 69:1051. 
 23 
 
 
Footnote: 
The authors have no commercial or other association that might pose a conflict of interest. 
 
Financial support:  Department of Health, Pennsylvania 
 
Address correspondence and reprint requests to Dr. Jongming Li, Department of Medical 
Oncology, 1024 Curtis Building, Thomas Jefferson University, 1015 Walnut St., Philadelphia, 
PA, USA 19107.  E-mail address: jongming.li@jefferson.edu. Telephone: 215 9553973. Fax: 215 
9230797 
 
 
 
 
 
 
 
Abbreviations used in this paper: 
EBV-associated post-transplant lymphoproliferative diseases     PTLD 
Hodgkin lymphoma        HL  
Nasopharyngeal carcinoma       NPC 
Adoptive cell transfer        ACT 
Dendritic cells        DC 
Normal AB serum       NABS 
Recombinant human IL-2      rhIL-2 
Flow cytometric intracellular cytokine assay    ICC 
10% normal AB serum/RPMI-1640     CM 
EBV transformed B lymphocyte                                                        LCL 
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Figure Legends 
 
Figure 1. Solid phase T cell selection. PBMC was activated by autologous irradiated 
LCL. LCL was immobilized on the glass. Activated lymphocytes were added, selected at 
various times and non-adherent cells were then removed by washing. 
 
Figure 2. Selection of EBV-specific T cell by immobilized LCL (Donor 1) 
A). Representative dot plots of 3 similar experiment results of T cell selection: the 
numbers in the upper right quadrants represent percent EBV-specific CD8+ T cells within 
gated CD3+ cells on the support surface after selection.  Selection times are indicated 
above the frame of dot plots. Data of T cells selected at 1, 10 and 15 minutes were not 
shown. B). Lymphocytes of Figure 2A were expanded after selection. The numbers in 
the upper right quadrants represent percent EBV-specific CD8+ T cells within gated 
CD3+ cells. Selection times are indicated above the frame of dot plots. Representative 
dot plots of 3 similar experiment results of 3 and 5 minutes selection were shown. Data of 
expanded T cells selected at 10 and 15 minutes were not shown. C). Of lymphocytes 
shown in Figure 2B, LMP2 (LLW, CLG & FLY)-specific T cells were measured as 
percent (mean, +SD) IFN-γ+ CD8+ T cells within gated CD3+ cells. The numbers in the 
upper right quadrants represent percent LMP2 (LLW, CLG & FLY)-specific CD8+ T 
cells within gated CD3+ cells. Selection times are indicated above the frame of dot plots. 
Representative dot plots of 3 similar experiment results of 3 and 5 minutes selection were 
shown. Data of expanded T cells selected at 10 and 15 minutes were not shown. D). 
EBV-specific T cells were measured as percent (mean, +SD) IFN-γ+ positive CD8+ T 
cells within gated CD3+ T cells on day 0, 1, 2 and 7 after selection. E). Lymphocytes 
generated from various selection times lyse autologous LCL, whereas there is no 
significant percent lysis of K562 and LCL when MHC I antibody (w6/32) was added to 
the latter (cytotoxicity data from 5 minutes selection T cells were shown as 
representative). Each point represents the mean of data from triplicate experiments. 
 
Figure 3. LMP2-specific T cell selection with immobilized LCL (donor 5). 
A). Representative dot plots of 3 similar experiment results of CLG-specific T cell 
selection: the numbers in the upper right quadrants represent percent CLG-specific CD8+ 
T cells within gated CD3+ cells on the support surface after selection.  Selection times 
are indicated above the frame of dot plots. Data of T cells selected at 3 and 15 minutes 
were not shown. B). Lymphocytes of Figure 3A were expanded after selection (7.5 
minutes). Representative dot plots of ICC and tetramer assay of 3 similar experiment 
results were shown: the numbers in the upper right quadrants represent percent CLG-
specific CD8+ T cells within gated CD3+ cells. Selection times are indicated above the 
frame of dot plots of ICC and tetramer assay. C). CLG-specific T cells generated by 
CLG-pulsed-LCL selection lyse T2 cell line pulsed with CLG and do not have significant  
killings of T2 cell line pulsed with CMV pp64 peptide P495-503. Each point represents the 
mean of data from triplicate experiments.  
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Figure 4. LMP2-specific T cell selection with immobilized monocytes (donor 5). 
A). Representative dot plots of 3 similar experiment results of CLG-specific T cell 
selection: the numbers in the upper right quadrants represent percent CLG-specific CD8+ 
T cells within gated CD3+ cells on the support surface after selection.  Selection times 
are indicated above the frame of dot plots. Data of T cells selected at 1 and 3 minutes 
were not shown. B). Lymphocytes of Figure 4A were expanded after selection (7.5 
minutes). Representative dot plots of ICC and tetramer assay of 3 similar experiment 
results were shown: the numbers in the upper right quadrants represent percent CLG-
specific CD8+ T cells within gated CD3+ cells. Selection times are indicated above the 
frame of dot plots of ICC and tetramer assay. C). CLG-specific T cells generated by 
CLG-loaded-monocytes selection lyse T2 cell line pulsed with CLG and do not have 
significant killings of T2 cell line pulsed with CMV pp64 peptide P495-503. Each point 
represents the mean of data from triplicate experiments.  
 
 
 
